文献速递间质性肺疾病

BMI与体重变化和纤维化间质性肺疾病患者死亡风险的关联

Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease.
PubMed 文献 · Chest · 2021-11-14

该多中心回顾性队列研究基于加拿大CARE-PF(衍生队列,1,786例)和UCSF(验证队列,1,779例)纤维化ILD患者,评估BMI与体重变化对死亡率的预后价值。结果显示,低体重与死亡风险升高相关,超重/肥胖与风险降低相关,1年内体重下降≥2 kg与随后1年死亡风险升高独立相关,验证队列结果一致。

要点

  • 低体重(BMI<18.5)患者死亡风险显著高于正常体重者
  • 超重和肥胖患者死亡风险低于正常体重者
  • 1年内体重下降≥2 kg提示随后1年死亡风险升高

核心结论

  • BMI与体重下降均与纤维化ILD患者1年死亡率独立相关,可作为临床有用的预后指标。

研究设计与样本

  • 多中心回顾性观察性队列研究,衍生队列为加拿大CARE-PF(1,786例),验证队列为UCSF ILD登记(1,779例)。
  • 按BMI分为低体重(<18.5)、正常体重(18.5-24.9)、超重(25-29.9)和肥胖(>30)。
  • 体重年变化以最小二乘法拟合斜率计算,采用多变量分析校正常见预后变量。

主要发现

  • 校正ILD-GAP指数后,低体重者死亡风险最高(HR 3.19;95%CI 1.88-5.43;P<.001),超重者最低(HR 0.52;95%CI 0.36-0.75;P<.001),肥胖者为HR 0.55(95%CI 0.37-0.83;P<.001)。
  • 校正ILD-GAP指数和基线BMI类别后,1年内体重下降≥2 kg者随后1年死亡风险升高(HR 1.41;95%CI 1.01-1.97;P=.04),更大体重下降者风险趋于平台。
  • 验证队列观察到一致结果。

关键数值与推荐

  • 低体重:BMI<18.5;正常体重:BMI 18.5-24.9;超重:BMI 25-29.9;肥胖:BMI>30。
  • 1年内体重下降≥2 kg定义为具有预后意义的体重丢失阈值。

临床怎么用

  • 在纤维化ILD患者随访中可常规记录BMI与体重变化,低体重或1年内体重下降≥2 kg者提示预后不良,需加强评估与随访。

局限性

  • 为回顾性观察性研究,BMI与体重变化和死亡率的关联可能受未测量混杂因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mortality risk assessment in interstitial lung disease (ILD) is challenging. Our objective was to determine the prognostic significance of BMI and change in weight in the most common fibrotic ILD subtypes. RESEARCH QUESTION: Could BMI and weight loss over time be reliable prognostic indicators in patients with fibrotic ILD? STUDY DESIGN AND METHODS: This observational retrospective multicenter cohort study enrolled patients with fibrotic ILD from the six-center CAnadian REgistry for Pulmonary Fibrosis (CARE-PF, derivation) and the ILD registry at the University of California, San Francisco (UCSF, validation). Patients were subcategorized as underweight (BMI < 18.5), normal weight (BMI 18.5-24.9), overweight (BMI 25-29.9), or obese (BMI > 30). Annual change in weight was calculated for all years of follow-up as the slope of best fit using the least square method based on every available measurement. Separate multivariable analyses evaluated the associations of BMI and change in weight with mortality, adjusting for common prognostic variables. RESULTS: The derivation and validation cohorts included 1,786 and 1,779 patients, respectively. Compared with patients with normal BMI, mortality was highest in patients who were underweight (hazard ratio [HR], 3.19; 95% CI, 1.88-5.43; P < .001) and was lowest in those who were overweight (HR, 0.52; 95% CI, 0.36-0.75; P < .001) or obese (HR, 0.55; 95%CI, 0.37-0.83; P < .001) in the analysis adjusted for the ILD-GAP (gender, age, physiology) Index. Patients who had a weight loss of at least 2 kg within 1 year had increased risk of death in the subsequent year (HR, 1.41; 95% CI, 1.01-1.97; P = .04) after adjustment for the ILD-GAP Index and baseline BMI category, with a plateau in risk for patients with greater weight loss. Consistent results were observed in the validation cohort. INTERPRETATION: Both BMI and weight loss are independently associated with 1-year mortality in fibrotic ILD. BMI and weight loss may be clinically useful prognostic indicators in fibrotic ILD.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Comes A, Wong AW, Fisher JH, et al. Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. Chest. 2021. PMID: 34788669. doi:10.1016/j.chest.2021.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。